Respiratory Effectiveness Group (REG)

This sponsor has funded 19 studies across 10 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
4238 Finalised Not included in RMP A RETROSPECTIVE, REAL-LIFE EVALUATION OF THE CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH EXPOSURE TO PHARMACOLOGICAL SMOKING CESSATION INTERVENTIONS... Yes No
4860 Finalised Not included in RMP Validation of real-life asthma research endpoints (Real-life asthma endpoint validation) Yes No
4869 Finalised Not included in RMP Using real-life patient records to help identify predictors of future exacerbation risk (Asthma risk predictors) Yes No
4891 Finalised Not included in RMP EXPLORING THE BIDIRECTIONAL RELATIONSHIP BETWEEN DATABASE MARKERS OF ASTHMA TREATMENT ADHERENCE AND ASTHMA-RELATED OUTCOMES (ICS ADHERENCE & ASTHMA... Yes No
4921 Finalised Not included in RMP THE RELIABILITY AND UTILITY OF BLOOD EOSINOPHILS AS A MARKER OF DISEASE BURDEN, HEALTHCARE RESOURCE UTILISATION IN CHRONIC OBSTRUCTIVE PULMONARY... Yes No
5032 Ongoing Not included in RMP The healthcare costs associated with comorbidities of refractory asthma and systemic steroid exposure in the UK (Refractory Asthma & Steroid Exposure) Yes No
8740 Finalised Unspecified State of the Union: Current asthma morbidity in the UK No No
10483 Finalised Unspecified Increasing ICS Dose vs Add-on Therapy in Children with Asthma (Paediatric Asthma Step-up) Yes No
10679 Finalised Not included in RMP Evaluation of COPD Control and its Clinical Implications in a Real-Life UK Primary Care Population Yes No
10684 Ongoing Not included in RMP Comparative Effectiveness of Extra-Fine Particle Inhaled Corticosteroid (ICS) and Alternative Guideline-Recommended Step-Up Options in Pre-School... Yes No
11656 Finalised Not included in RMP Validation of the Concept of COPD Control in Clinical Practice Yes No
12086 Finalised Not included in RMP IDENTIFYING OPPORTUNITIES FOR EARLIER DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS IN ROUTINE CARE IN THE UK: A RETROSPECTIVE CLINICAL COHORT STUDY... Yes No
12132 Finalised Not included in RMP ADDITION OF ANTIBIOTICS TO USUAL CARE MANAGEMENT OF ASTHMA EXACERBATIONS: A REALLIFE COMPARATIVE EFFECTIVENESS STUDY Yes No
13959 Finalised Not included in RMP COMPARABILITY OF POPULATION DEFINITIONS WITHIN & BETWEEN GLOBAL DATABASES – DEVELOPING TOOLS FOR OBSERVATIONAL RESEARCH (ACO Population Definitions) No No
17985 Finalised Not included in RMP A prediction model for future exacerbation risk in children Yes No
19984 Finalised Not included in RMP Impact of obstructive sleep apnea diagnosis on healthcare resource utilization in patients with obstructive lung disease Yes No
21791 Finalised Not included in RMP Epidemiological trends of Alpha1-antitrypsin deficiency (AATD) in the UK: prevalence and incidence from 1990 to 2015 Yes No
28667 Finalised Not included in RMP Evaluation of Current Implementation of BTS/NICE Clinical Quality Standards In Community Acquired Pneumonia (CAP): A UK retrospective follow-up study Yes No
30625 Ongoing Not included in RMP Burden of cough in primary care Yes No

PAS by Risk Management Plan (RMP) requirement

Respiratory Effectiveness Group (REG)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.